Leptomeningeal Metastasis Clinical Trial
Official title:
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors： a Phase I/II Study
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors, to evaluate the safety and efficacy.
This is an open-label, single-arm, phase I/II trial of immune checkpoint inhibitor combined with pemetrexed intrathecal injection for leptomeningeal metastasis from solid tumors. The primary endpoint of the phase I study was to determine the recommended phase II dose (PR2D). The primary endpoint of the Phase II study was to assess the safety and clinical response rate of immune checkpoint inhibitor in combination with pemetrexed intrathecally under PR2D, with secondary endpoints of overall survival, and neurological progression-free survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Completed |
NCT04178343 -
Tomotherapy for Leptomeningeal Metastases
|
N/A | |
| Recruiting |
NCT06399926 -
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir
|
||
| Not yet recruiting |
NCT06441045 -
Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI
|
Phase 2 | |
| Recruiting |
NCT04425681 -
Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05598853 -
Intrathecal Double Checkpoint Inhibition
|
Phase 1 | |
| Recruiting |
NCT02803619 -
A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis
|
N/A | |
| Recruiting |
NCT05746754 -
Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis
|
N/A | |
| Not yet recruiting |
NCT04148898 -
Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis
|
Phase 2 | |
| Completed |
NCT04420598 -
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
|
Phase 2 | |
| Completed |
NCT02071056 -
Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)
|
||
| Recruiting |
NCT05385185 -
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
|
Phase 2 | |
| Terminated |
NCT04729348 -
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
|
Phase 2 | |
| Recruiting |
NCT06304441 -
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
|
N/A | |
| Not yet recruiting |
NCT06296745 -
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
|
Phase 2 | |
| Recruiting |
NCT04778800 -
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
|
N/A | |
| Not yet recruiting |
NCT06282874 -
Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases
|
Phase 4 | |
| Not yet recruiting |
NCT04356222 -
Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
|
Phase 4 | |
| Not yet recruiting |
NCT04356118 -
Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
|
Phase 4 |